| AdComm member quits over FDA approval of Biogen's Aduhelm AbbVie snags another preclinical Parkinson's program with $17M Caraway pact Editor's Corner—The FDA's decision on aducanumab will drag down innovation for years to come Sponsored: In a Year of Crisis, Maryland Biotech Responds with Leadership Kojin bags $60M to exploit weakness of drug-resistant cancers Sponsored: Innovative POC MATLOC Digital Device for CKD Alcyone Therapeutics picks up $23M in hopes of being a star in treating CNS disorders Byondis ready to link up to bring Herceptin-booster to market after phase 3 win Boehringer Ingelheim taps into Lifebit's AI for global disease surveillance Featured Story | By Nick Paul Taylor A member of the advisory committee that recommended rejecting Biogen’s aducanumab has quit over the FDA’s approval of the drug, Stat reports. Washington University neurologist Joel Perlmutter left “due to this ruling by the FDA without further discussion with our advisory committee.” read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Caraway Therapeutics wasn’t going to partner off its Parkinson’s program for a few more years, but AbbVie came along with an offer it couldn’t refuse. The Big Pharma handed over $17 million upfront for the option to license Caraway’s program targeting TMEM175, with the promise of $250 million more. read more By Ben Adams The amyloid theory just won’t die. In fact, by approving Biogen's new Alzheimer's disease drug, the FDA has just resurrected it for a long and healthy future. This is great news for Biogen, but it will decimate Alzheimer’s research, faith in the agency and the healthcare budget for decades to come. read more Sponsored by: The State of Maryland Prior to the pandemic, nearly a quarter of Maryland’s biopharm and medical tech companies focused on infectious diseases. As COVID-19 spread, dozens of Maryland companies joined the global response. read more By Nick Paul Taylor Kojin Therapeutics has raised $60 million to use iron-dependent cell death to treat drug-resistant cancer. The series A round positions the biotech to build on the work its scientific founders did at institutions including Harvard University and Dana-Farber Cancer Institute. read more Sponsored By: Health Logic Health Logic Interactive is working on advanced technology called MATLOC that has the potential to revolutionize the Chronic Kidney Disease treatment space from the ground up. read more By Kyle LaHucik Alcyone Therapeutics looks to break into the severe CNS disorder landscape, include Rett Syndrome, with $23 million in funding and 12 adeno-associated virus gene therapy programs. read more By Kyle LaHucik A new linker drug from Byondis that boosts the targeting power of Roche's Herceptin helped patients with a certain type of advanced breast cancer live longer without disease progression in a phase 3 clinical trial. The Dutch biopharma is now ready to consider linking up with a partner to bring the therapy to market. read more By Conor Hale Boehringer Ingelheim's ambitious project with AI developer Lifebit aims to use natural language processing to help chart a course among new global outbreaks of infectious diseases. read more | | Health Care Is Home Care From study drug administration to blood draws, Marken’s fully integrated home healthcare solutions make participation in clinical research as simple as possible for patients. Learn more. |
Resources Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by SDG Group Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Next Gen: What’s beyond the leading edge of biotech and pharma? June 22-23, 2021 | Virtual Event Biopharma Supply Chain June 29-30, 2021 | Virtual Event | 